Literature DB >> 17127545

Evidence-based treatment for opiate-dependent clients: availability, variation, and organizational correlates.

Lori J Ducharme1, Hannah K Knudsen, Paul M Roman.   

Abstract

The majority of opiate-dependent clients entering substance abuse treatment are referred to "drug-free" (non-methadone) modalities. Given the known challenges of treating these clients in drug-free settings relative to the documented effectiveness of methadone maintenance, these analyses investigate the availability of various clinical and wraparound services for this population among a US sample of addiction treatment programs with and without methadone maintenance services (N = 763). Face-to-face interviews conducted in 2002-2003 gathered data on the number of opiate-dependent clients treated; organizational characteristics, including size, ownership, accreditation, and staffing; treatment practices, including methadone availability, use of other pharmacotherapies, and levels of care; and services offered, including vouchers, transportation, and other wraparound services. Facilities treating proportionately more opiate-dependent clients were significantly more likely to offer a variety of evidence-based services, regardless of methadone availability. Implications for referral linkages and quality of care are discussed.

Entities:  

Mesh:

Year:  2006        PMID: 17127545     DOI: 10.1080/00952990600920417

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  10 in total

1.  The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.

Authors:  Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2010-02-01

2.  A categorical typology of naltrexone-adopting private substance abuse treatment centers.

Authors:  Carrie B Oser; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2007-11-07

3.  Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication.

Authors:  Stanley S Wallack; Cindy Parks Thomas; Timothy C Martin; Jon Chilingerian; Sharon Reif
Journal:  J Behav Health Serv Res       Date:  2008-07-31       Impact factor: 1.505

4.  The trouble with morality: the effects of 12-step discourse on addicts' decision-making.

Authors:  David Frank
Journal:  J Psychoactive Drugs       Date:  2011 Jul-Sep

5.  Comparing injection and non-injection routes of administration for heroin, methamphetamine, and cocaine users in the United States.

Authors:  Scott P Novak; Alex H Kral
Journal:  J Addict Dis       Date:  2011 Jul-Sep

6.  Despite Resources From The ACA, Most States Do Little To Help Addiction Treatment Programs Implement Health Care Reform.

Authors:  Christina Andrews; Amanda Abraham; Colleen M Grogan; Harold A Pollack; Clifford Bersamira; Keith Humphreys; Peter Friedmann
Journal:  Health Aff (Millwood)       Date:  2015-05       Impact factor: 6.301

7.  Differences between men and women in the course of opiate dependence: is there a telescoping effect?

Authors:  Frank Hölscher; Volker Reissner; Lucia Di Furia; Robin Room; Fabrizio Schifano; Rudolf Stohler; Vicky Yotsidi; Norbert Scherbaum
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-10-18       Impact factor: 5.270

8.  Management practices in substance abuse treatment programs.

Authors:  K John McConnell; Kim A Hoffman; Andrew Quanbeck; Dennis McCarty
Journal:  J Subst Abuse Treat       Date:  2009-02-04

Review 9.  Research on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review.

Authors:  Bryan R Garner
Journal:  J Subst Abuse Treat       Date:  2008-11-12

10.  Service delivery in substance abuse treatment: reexamining "comprehensive" care.

Authors:  Lori J Ducharme; Heather L Mello; Paul M Roman; Hannah K Knudsen; J Aaron Johnson
Journal:  J Behav Health Serv Res       Date:  2007-03-28       Impact factor: 1.475

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.